English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Our purpose was to evaluate an imaging parameter-response relationship between the extent of tumor hypoxia quantified by dynamic 18 F-fluoromisonidazole ( 18 F-FMISO) PET/CT and the risk of relapse after radiotherapy in patients with head and neck cancer. Methods: Before a prospective cohort of 25 head and neck cancer patients started radiotherapy, they were examined with dynamic 18 F-FMISO PET/CT 0-240 min after tracer injection. 18 F-FMISO image parameters, including a hypoxia metric, M   FMISO   , derived from pharmacokinetic modeling of dynamic 18 F-FMISO and maximum tumor-to-muscle ratio (TMR max ) at 4 h after injection, gross tumor volume (GTV), relative hypoxic volume based on M   FMISO   , and a logistic regression model combining GTV and TMR max , were assessed and compared with a previous training cohort ( n = 15). Dynamic 18 F-FMISO was used to validate a tumor control probability model based on M   FMISO  The prognostic potential with respect to local control of all potential parameters was validated using the concordance index for univariate Cox regression models determined from the training cohort, in addition to Kaplan-Meier analysis including the log-rank test. Results: The tumor control probability model was confirmed, indicating that dynamic 18 F-FMISO allows stratification of patients into different risk groups according to radiotherapy outcome. In this study, M   FMISO  was the only parameter that was confirmed as prognostic in the independent validation cohort (concordance index, 0.71; P = 0.004). All other investigated parameters, such as TMR max , GTV, relative hypoxic volume, and the combination of GTV and TMR max , were not able to stratify patient groups according to outcome in this validation cohort ( P = not statistically significant). Conclusion: In this study, the relationship between M   FMISO  and the risk of relapse was prospectively validated. The data support further evaluation and external validation of dynamic 18 F-FMISO PET/CT as a promising method for patient stratification and hypoxia-based radiotherapy personalization, including dose painting.

Prospective Evaluation of a Tumor Control Probability Model Based on Dynamic 18F-FMISO PET for Head and Neck Cancer Radiotherapy

Prospective Evaluation of a Tumor Control Probability Model Based on Dynamic ¹⁸F-FMISO PET for Head and Neck Cancer Radiotherapy